284 related articles for article (PubMed ID: 30783518)
1. Targeted human cytolytic fusion proteins at the cutting edge: harnessing the apoptosis-inducing properties of human enzymes for the selective elimination of tumor cells.
Mungra N; Jordaan S; Hlongwane P; Naran K; Chetty S; Barth S
Oncotarget; 2019 Jan; 10(8):897-915. PubMed ID: 30783518
[TBL] [Abstract][Full Text] [Related]
2. Updates in the Development of ImmunoRNases for the Selective Killing of Tumor Cells.
Jordaan S; Akinrinmade OA; Nachreiner T; Cremer C; Naran K; Chetty S; Barth S
Biomedicines; 2018 Mar; 6(1):. PubMed ID: 29510557
[TBL] [Abstract][Full Text] [Related]
3. Human Granzyme B Based Targeted Cytolytic Fusion Proteins.
Hlongwane P; Mungra N; Madheswaran S; Akinrinmade OA; Chetty S; Barth S
Biomedicines; 2018 Jun; 6(2):. PubMed ID: 29925790
[TBL] [Abstract][Full Text] [Related]
4. Granzyme M as a novel effector molecule for human cytolytic fusion proteins: CD64-specific cytotoxicity of Gm-H22(scFv) against leukemic cells.
Schiffer S; Letzian S; Jost E; Mladenov R; Hristodorov D; Huhn M; Fischer R; Barth S; Thepen T
Cancer Lett; 2013 Dec; 341(2):178-85. PubMed ID: 23973499
[TBL] [Abstract][Full Text] [Related]
5. Advances in epidermal growth factor receptor specific immunotherapy: lessons to be learned from armed antibodies.
Biteghe FAN; Mungra N; Chalomie NET; Ndong JC; Engohang-Ndong J; Vignaux G; Padayachee E; Naran K; Barth S
Oncotarget; 2020 Sep; 11(38):3531-3557. PubMed ID: 33014289
[TBL] [Abstract][Full Text] [Related]
6. Designing the Sniper: Improving Targeted Human Cytolytic Fusion Proteins for Anti-Cancer Therapy via Molecular Simulation.
Bochicchio A; Jordaan S; Losasso V; Chetty S; Perera RC; Ippoliti E; Barth S; Carloni P
Biomedicines; 2017 Feb; 5(1):. PubMed ID: 28536352
[TBL] [Abstract][Full Text] [Related]
7. Human MAP Tau Based Targeted Cytolytic Fusion Proteins.
Akinrinmade OA; Jordaan S; Hristodorov D; Mladenov R; Mungra N; Chetty S; Barth S
Biomedicines; 2017 Jun; 5(3):. PubMed ID: 28653985
[TBL] [Abstract][Full Text] [Related]
8. A novel approach for targeted elimination of CSPG4-positive triple-negative breast cancer cells using a MAP tau-based fusion protein.
Amoury M; Mladenov R; Nachreiner T; Pham AT; Hristodorov D; Di Fiore S; Helfrich W; Pardo A; Fey G; Schwenkert M; Thepen T; Kiessling F; Hussain AF; Fischer R; Kolberg K; Barth S
Int J Cancer; 2016 Aug; 139(4):916-27. PubMed ID: 27037627
[TBL] [Abstract][Full Text] [Related]
9. Human cancer detection and immunotherapy with conjugated and non-conjugated monoclonal antibodies.
Bodey B; Siegel SE; Kaiser HE
Anticancer Res; 1996; 16(2):661-74. PubMed ID: 8687112
[TBL] [Abstract][Full Text] [Related]
10. Granzyme B-based cytolytic fusion protein targeting EpCAM specifically kills triple negative breast cancer cells in vitro and inhibits tumor growth in a subcutaneous mouse tumor model.
Amoury M; Kolberg K; Pham AT; Hristodorov D; Mladenov R; Di Fiore S; Helfrich W; Kiessling F; Fischer R; Pardo A; Thepen T; Hussain AF; Nachreiner T; Barth S
Cancer Lett; 2016 Mar; 372(2):201-9. PubMed ID: 26806809
[TBL] [Abstract][Full Text] [Related]
11. Novel therapeutic strategies to selectively kill cancer cells.
Panchal RG
Biochem Pharmacol; 1998 Feb; 55(3):247-52. PubMed ID: 9484789
[TBL] [Abstract][Full Text] [Related]
12. A novel fully-human cytolytic fusion protein based on granzyme B shows in vitro cytotoxicity and ex vivo binding to solid tumors overexpressing the epidermal growth factor receptor.
Niesen J; Hehmann-Titt G; Woitok M; Fendel R; Barth S; Fischer R; Stein C
Cancer Lett; 2016 May; 374(2):229-40. PubMed ID: 26912070
[TBL] [Abstract][Full Text] [Related]
13. Engineered human angiogenin mutations in the placental ribonuclease inhibitor complex for anticancer therapy: Insights from enhanced sampling simulations.
Cong X; Cremer C; Nachreiner T; Barth S; Carloni P
Protein Sci; 2016 Aug; 25(8):1451-60. PubMed ID: 27110669
[TBL] [Abstract][Full Text] [Related]
14. CSPG4: A Target for Selective Delivery of Human Cytolytic Fusion Proteins and TRAIL.
Jordaan S; Chetty S; Mungra N; Koopmans I; van Bommel PE; Helfrich W; Barth S
Biomedicines; 2017 Jun; 5(3):. PubMed ID: 28657611
[TBL] [Abstract][Full Text] [Related]
15. Human microtubule-associated protein tau mediates targeted killing of CD30(+) lymphoma cells in vitro and inhibits tumour growth in vivo.
Hristodorov D; Nordlohne J; Mladenov R; Huhn M; Fischer R; Thepen T; Barth S
Br J Haematol; 2014 Jan; 164(2):251-7. PubMed ID: 24164493
[TBL] [Abstract][Full Text] [Related]
16. Restoration of DAP Kinase Tumor Suppressor Function: A Therapeutic Strategy to Selectively Induce Apoptosis in Cancer Cells Using Immunokinase Fusion Proteins.
Tur MK; Daramola AK; Gattenlöhner S; Herling M; Chetty S; Barth S
Biomedicines; 2017 Oct; 5(4):. PubMed ID: 28976934
[TBL] [Abstract][Full Text] [Related]
17. Targeted ex vivo reduction of CD64-positive monocytes in chronic myelomonocytic leukemia and acute myelomonocytic leukemia using human granzyme B-based cytolytic fusion proteins.
Schiffer S; Rosinke R; Jost E; Hehmann-Titt G; Huhn M; Melmer G; Barth S; Thepen T
Int J Cancer; 2014 Sep; 135(6):1497-508. PubMed ID: 24523193
[TBL] [Abstract][Full Text] [Related]
18. Modularly Constructed Synthetic Granzyme B Molecule Enables Interrogation of Intracellular Proteases for Targeted Cytotoxicity.
Ho P; Ede C; Chen YY
ACS Synth Biol; 2017 Aug; 6(8):1484-1495. PubMed ID: 28510446
[TBL] [Abstract][Full Text] [Related]
19. Advanced targeted therapies in cancer: Drug nanocarriers, the future of chemotherapy.
Pérez-Herrero E; Fernández-Medarde A
Eur J Pharm Biopharm; 2015 Jun; 93():52-79. PubMed ID: 25813885
[TBL] [Abstract][Full Text] [Related]
20. Targeted cancer therapy: conferring specificity to cytotoxic drugs.
Chari RV
Acc Chem Res; 2008 Jan; 41(1):98-107. PubMed ID: 17705444
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
